PubMed=15994418; DOI=10.1093/jhered/esi085
Winkler S., Murua Escobar H., Eberle N., Reimann-Berg N., Nolte I., Bullerdiek J.
Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype.
J. Hered. 96:782-785(2005)

PubMed=18706092; DOI=10.1186/1471-2407-8-240
Fork M.A.M., Murua Escobar H., Soller J.T., Sterenczak K.A., Willenbrock S., Winkler S., Dorsch M., Reimann-Berg N., Hedrich H.J., Bullerdiek J., Nolte I.
Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258.
BMC Cancer 8:240.1-240.8(2008)

PubMed=24324078
Moulay M., Liu W., Willenbrock S., Sterenczak K.A., Carlson R., Ngezahayo A., Murua Escobar H., Nolte I.
Evaluation of stem cell marker gene expression in canine prostate carcinoma- and prostate cyst-derived cell lines.
Anticancer Res. 33:5421-5431(2013)

PubMed=24914948; DOI=10.1371/journal.pone.0098788
Willenbrock S., Wagner S., Reimann-Berg N., Moulay M., Hewicker-Trautwein M., Nolte I., Murua Escobar H.
Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model.
PLoS ONE 9:E98788-E98788(2014)

PubMed=26774145; DOI=10.4149/208_150924N505
Hammer S.C., Nagel S., Junginger J., Hewicker-Trautwein M., Wagner S., Heisterkamp A., Ngezahayo A., Nolte I., Murua Escobar H.
Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines.
Neoplasma 63:231-238(2016)

PubMed=32168360; DOI=10.1371/journal.pone.0230272
Packeiser E.-M., Hewicker-Trautwein M., Thiemeyer H., Mohr A., Junginger J., Schille J.T., Murua Escobar H., Nolte I.
Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
PLoS ONE 15:E0230272-E0230272(2020)

PubMed=32368185; DOI=10.1186/s12935-020-01211-0
Liu W., Sender S., Kong W.-B., Beck J., Sekora A., Bornemann-Kolatzki K., Schutz E., Junghanss C., Brenig B., Nolte I., Murua Escobar H.
Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines.
Cancer Cell Int. 20:139.1-139.11(2020)

PubMed=35109825; DOI=10.1186/s12935-021-02422-9
Packeiser E.-M., Taher L., Kong W.-B., Ernst M., Beck J., Hewicker-Trautwein M., Brenig B., Schutz E., Murua Escobar H., Nolte I.
RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.
Cancer Cell Int. 22:54.1-54.21(2022)